Avian Diseases最新文献

Avian reovirus (ARV) is highly disseminated in commercial Brazilian poultry farms, causing arthritis/tenosynovitis, runting-stunting syndrome, and malabsorption syndrome in different meat- and egg-type birds (breeders, broilers, grillers, and layers). In Brazil, ARV infection was first described in broilers in the 1970s but was not considered an important poultry health problem for decades. A more concerning outcome of field infections has been observed in recent years, including condemnations at slaughterhouses because of the unsightly appearance of chicken body parts, mainly the legs. Analyses of the performance of poultry flocks have further evidenced economic losses to farms. Genetic and antigenic characterization of ARV field strains from Brazil demonstrated a high diversity of lineages circulating in the entire country, including four of the five main phylogenetic groups previously described (I, II, III, and V). It is still unclear if all of them are associated with different diseases affecting flocks' performance in Brazilian poultry. ARV infections have been controlled in Brazilian poultry farms by immunization of breeders and young chicks with classical commercial live vaccine strains (S1133, 1733, 2408, and 2177) used elsewhere in the Western Hemisphere. However, genetic and antigenic variations of the field isolates have prevented adequate protection against associated diseases, so killed autogenous vaccines are being produced from isolates obtained on specific farms. In conclusion, ARV field variants are continuously challenging poultry farming in Brazil. Epidemiological surveillance combined with molecular biological analyses from the field samples, as well as the development of vaccine strains directed toward the ARV circulating variants, are necessary to control this economically important poultry pathogen.

Avian reovirus (ARV) has been determined to be the etiologic agent of viral arthritis/tenosynovitis. In Israel, meat-type chickens, including broilers and breeders, are the most affected. Severe disease symptoms can appear in broiler flocks at a very young age because of early exposure and vertical transmission, causing significant welfare problems. Jewish laws define birds with inflamed, damaged, or torn gastrocnemius and digital flexor tendons as religious condemnations (non-kosher), resulting in severe economic losses for the poultry industry. Vaccination of breeders is a strategy to control the disease by reducing vertical transmission and providing maternal-derived antibodies to the progeny. This review describes Israel's ARV variants and the various vaccines developed over the years. Identification of co-circulating variants triggered the development of multivalent autogenous inactivated vaccines. However, the genotype-matched vaccines failed to provide protection, resulting in an increased prevalence of Cluster II ARV (classified as genotyping cluster 5 in the ARV common world classification). Since 2014, ARV Cluster II has been dominant in Israel. In 2015, the dominant variant s7585 tropism changed the virus pathogenesis and affected broilers with severe clinical signs between 12 and 15 days of age. A new vaccine approach developed in Israel used controlled exposure of the breeding flock to virulent ARV at the age when they are resistant to infection. This approach significantly reduced clinical field cases and reovirus isolations of breeding and broiler flocks between 2020 and 2022.

Escherichia coli (E. coli) is a commensal bacteria found in the gastrointestinal tract of poultry; however, some strains are pathogenic and can cause a wide range of diseases. In addition, some strains of pathogenic E. coli can survive in the litter between flocks, making litter management critical for reducing E. coli-associated infections. Biochar (BC) is a porous, carbonaceous material that may be a beneficial litter amendment to reduce moisture and microbial loads. The objectives of this study were to evaluate the effects of pine BC, miscanthus BC, and Poultry Litter Treatment (PLT) on E. coli, total aerobic bacteria populations, and bacterial communities when added to used broiler litter. Pine and miscanthus BC were mixed into poultry litter at inclusion rates of 5%, 10%, 20%, 25%, and 30% w/w. PLT was surface applied at a rate of 0.73 kg/m². Baseline E. coli and aerobics were measured after a 48-hr litter incubation period and just prior to adding litter treatments. Escherichia coli and aerobics were enumerated 2 and 7 days after adding treatments. Overall, pine BC at 30% had the lowest E. coli and aerobic counts (5.98 and 6.44 log ₁₀ colony-forming units [CFU]/g, respectively); however, they were not significantly different from the control (P ≤ 0.05). At day 2, 30% pine BC inclusion rate treatment resulted in a significant reduction in E. coli and aerobic bacteria counts compared to the control. Miscanthus BC application did not result in significant reductions in E. coli or aerobic bacteria at days 2 or 7. PLT had the highest E. coli (7.07 log ₁₀ CFU/g) and aerobic counts (7.21 log ₁₀ CFU/g) overall. Bacterial community analysis revealed that the alpha and beta diversity between pine BC- and PLT-treated litter were significantly different. However, neither BC type significantly impacted bacterial diversity when compared to the control. Differences in E. coli and aerobic counts between BC types may be attributed to variations in feedstock physiochemical properties.

Viral arthritis/tenosynovitis, a disease caused by avian reovirus (ARV), leads to great economic losses for the chicken industry worldwide. Since autumn 2011, the poultry industries in the United States and Canada have sustained significant economic losses in the progeny of broiler breeders vaccinated with classic strains of ARV. Vaccination failure has been caused by field challenge with variant ARVs. The variant field ARVs are refractory to the immunity stimulated by classic vaccines and have become the prevalent challenge in the field. Because all genotypes described in the literature have been reported to be circulating in Canada, genotyping of circulating ARVs is paramount for the selection of appropriate isolates, representative of the field challenge, for use in autogenous vaccines. In this review, the history of ARVs and the current situation in Canada are discussed. On the basis of recent field data, inadequate measures commonly used in the field are discussed, and successful vaccination strategies are recommended.

Avian reoviruses are ubiquitous in poultry production worldwide and can be transmitted vertically or horizontally among chickens. The pathogenicity of reoviruses can range from very pathogenic viruses that affect multiple tissues and organs to apathogenic. Avian reoviruses have been associated with many disease presentations, and two of the most economically significant diseases are viral arthritis/tenosynovitis and viral enteritis. Viral arthritis/tenosynovitis has been recognized since the 1950s and essentially disappeared after development of attenuated live and inactivated vaccines in the 1980s but re-emerged in 2011 due to the emergence of antigenic variants. Viral enteritis was first recognized in the 1970s and became the predominant reovirus-associated disease between 2006 and 2011 due to the emergence of pathogenic enterotropic reoviruses. Pathogenicity of reovirus isolates can be evaluated in several ways, including inoculation of day-old broiler chicks with low maternal reovirus antibody titers via the foot pad route or the oral and intratracheal route. Pathogenic reoviruses induce foot pad inflammation within 3 days of inoculation, and more pathogenic reoviruses are able to disseminate to and damage visceral organs. Only reovirus infections in young chickens result in disease due to age-related resistance to disease development. Reoviruses exist as many serotypes and subtypes with various degrees of interrelatedness. The earliest reovirus strains in the United States were antigenically related to each other and are referred to as S1133-like viruses, but in the 2000s, reoviruses emerged that were antigenically different from the S1133-like viruses. Virus neutralization assay using polyclonal antisera has been used to classify the emerging variant reoviruses into serogroups. The first reovirus vaccines were developed in the 1970s, and by the 1980s breeder vaccination programs were established that protected breeders, prevented vertical transmission of reovirus, and provided maternal immunity to the progeny during the crucial first 3 wk of life. With the emergence of antigenic variant reoviruses in the 2000s, vaccination programs using S1133-like vaccines became ineffective. The poultry industry has relied on vaccination with autogenous inactivated reovirus vaccines to alleviate losses due to viral arthritis/tenosynovitis and viral enteritis. Virus isolates used for autogenous vaccines must be updated regularly and are selected based on pathotype, serotype, or Sigma C (σC) genotype. Live attenuated S1133 vaccines are still used in breeder chickens for the priming effect, followed by one or more injections of the inactivated licensed and/or autogenous vaccines. The route of vaccination and the number of doses received by breeder chickens are very important for a sufficient antibody response. Intramuscular vaccination with inactivated vaccines elicits the highest antibody response, while subcutaneous vaccination with inactivated vacci

Since mid-2015, there has been an increasing number of chicken samples that are positive for infectious bronchitis virus (IBV) in a screening PCR but which do not show positive results in any established, variant-specific PCR tests (793B, QX, D1466, Massachusetts, D274, Italy 02, Arkansas, Variant 2, Q1). Partial sequencing of the viral genome of those samples shows great similarities, but nucleotide similarity in the S1 gene is only about 57%-61% when compared to any other known GI-GVII IBV genotype and lineage. With nucleotide identity in the S1 gene of approximately 80%, the closest related strain in the National Center for Biotechnology Information database (as of March 15, 2020) is the North American PA/1220/98 isolate (AY789942) designated as a unique variant by Valastro et al. in 2016. Due to its divergence from other IBV strains, we propose that strain, designated IB80, is the type strain of a novel IBV genotype GVIII. So far, IB80 has been detected in commercial layer and broiler parent flocks, frequently showing severe drops in egg production as well as in broiler flocks in Europe and beyond.